Literature DB >> 23065408

Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.

Aaron T Gerds1, Bart L Scott.   

Abstract

Paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome are a spectrum of acquired marrow failure, having a common pathologic thread of both immune dysregulation and the development of abnormal hematopoiesis. Allogeneic hematopoietic cell transplantation plays a critical role in the treatment of these disorders and, for many patients, is the only treatment modality with demonstrated curative potential. In recent years, there have been many breakthroughs in the understanding of the pathogenesis of these uncommon disorders. The subsequent advances in non-transplant therapies, along with concurrent improvement in outcomes after hematopoietic cell transplantation, necessitate continual appraisal of the indications, timing, and approaches to transplantation for acquired marrow failure syndromes. We review here contemporary and critical new findings driving current treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23065408      PMCID: PMC3640337          DOI: 10.1007/s11899-012-0138-x

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  39 in total

1.  Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.

Authors:  Julie Schanz; Christian Steidl; Christa Fonatsch; Michael Pfeilstöcker; Thomas Nösslinger; Heinz Tuechler; Peter Valent; Barbara Hildebrandt; Aristoteles Giagounidis; Carlo Aul; Michael Lübbert; Reinhard Stauder; Otto Krieger; Guillermo Garcia-Manero; Hagop Kantarjian; Ulrich Germing; Detlef Haase; Elihu Estey
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.

Authors:  Judith C Marsh; Vikas Gupta; Ziyi Lim; Aloysius Y Ho; Robin M Ireland; Janet Hayden; Victoria Potter; Mickey B Koh; M Serajul Islam; Nigel Russell; David I Marks; Ghulam J Mufti; Antonio Pagliuca
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

3.  Comparison between matched related and alternative donors of allogeneic hematopoietic stem cells transplanted into adult patients with acquired aplastic anemia: multivariate and propensity score-matched analysis.

Authors:  Hawk Kim; Byung Soo Kim; Dong Hwan Kim; Myung Soo Hyun; Sung Hyun Kim; Sung Hwa Bae; Jung Hye Choi; Sang Kyun Sohn; Ho Jin Shin; Jong Ho Won; Sung-Soo Yoon; Deog-Yoen Jo; Young Don Joo; Jae-Hoo Park; Kyoo-Hyung Lee
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-08       Impact factor: 5.742

4.  Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.

Authors:  Masha Fridkis-Hareli; Michael Storek; Istvan Mazsaroff; Antonio M Risitano; Ante S Lundberg; Christopher J Horvath; V Michael Holers
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

5.  Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.

Authors:  Mary Eapen; Jennifer Le Rademacher; Joseph H Antin; Richard E Champlin; Jeanette Carreras; Joseph Fay; Jakob R Passweg; Jakub Tolar; Mary M Horowitz; Judith C W Marsh; H Joachim Deeg
Journal:  Blood       Date:  2011-06-15       Impact factor: 22.113

6.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Georg N Franke; Ginna G Laport; Thomas R Chauncey; Edward Agura; Richard T Maziarz; Amelia Langston; Parameswaran Hari; Michael A Pulsipher; Wolfgang Bethge; Firoozeh Sahebi; Benedetto Bruno; Michael B Maris; Andrew Yeager; Finn Bo Petersen; Lars Vindeløv; Peter A McSweeney; Kai Hübel; Marco Mielcarek; George E Georges; Dietger Niederwieser; Karl G Blume; David G Maloney; Rainer Storb
Journal:  JAMA       Date:  2011-11-02       Impact factor: 56.272

7.  Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation.

Authors:  Regis Peffault de Latour; Duncan Purtill; Annalisa Ruggeri; Guillermo Sanz; Gerard Michel; Virginie Gandemer; Sebastien Maury; Joanne Kurtzberg; Carmen Bonfim; Mahmoud Aljurf; Eliane Gluckman; Gerard Socié; Jakob Passweg; Vanderson Rocha
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-16       Impact factor: 5.742

8.  Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

Authors:  Richard J Kelly; Anita Hill; Louise M Arnold; Gemma L Brooksbank; Stephen J Richards; Matthew Cullen; Lindsay D Mitchell; Dena R Cohen; Walter M Gregory; Peter Hillmen
Journal:  Blood       Date:  2011-04-01       Impact factor: 22.113

9.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Authors:  Julie Schanz; Heinz Tüchler; Francesc Solé; Mar Mallo; Elisa Luño; José Cervera; Isabel Granada; Barbara Hildebrandt; Marilyn L Slovak; Kazuma Ohyashiki; Christian Steidl; Christa Fonatsch; Michael Pfeilstöcker; Thomas Nösslinger; Peter Valent; Aristoteles Giagounidis; Carlo Aul; Michael Lübbert; Reinhard Stauder; Otto Krieger; Guillermo Garcia-Manero; Stefan Faderl; Sherry Pierce; Michelle M Le Beau; John M Bennett; Peter Greenberg; Ulrich Germing; Detlef Haase
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

10.  Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Authors:  U Platzbecker; M Wermke; J Radke; U Oelschlaegel; F Seltmann; A Kiani; I-M Klut; H Knoth; C Röllig; J Schetelig; B Mohr; X Graehlert; G Ehninger; M Bornhäuser; C Thiede
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

View more
  1 in total

1.  Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome.

Authors:  Yan-Fung Wong; Chris N Micklem; Masataka Taguchi; Hidehiro Itonaga; Yasushi Sawayama; Daisuke Imanishi; Shinichi Nishikawa; Yasushi Miyazaki; Lars Martin Jakt
Journal:  Stem Cells Transl Med       Date:  2014-08-13       Impact factor: 6.940

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.